Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
, 39 (3), 238-46

Treatment of Hepatitis C Virus Infection and Associated Vascular Complications: A Literature Review

Affiliations
Review

Treatment of Hepatitis C Virus Infection and Associated Vascular Complications: A Literature Review

Reza Karbasi-Afshar. Iran J Med Sci.

Abstract

Interferon (IFN)-based therapy, the cornerstone for treatment of hepatitis C virus (HCV) infection, is generally considered to be the single most effective treatment strategy for this infection. Although most adverse effects of IFN therapy respond very well to the cessation of this drug, there are reports of serious irreversible adverse effects. This review article evaluates the adverse effects of IFN therapy in HCV-infected patients. We have undertaken an extensive search for articles regarding IFN and pegylated-IFN (PEG-IFN) therapy and their vascular complications using multiple sources that include PubMed, publishers' websites, and Google Scholar. The prevalence of ocular disorders in the early period (first 8 weeks) after IFN administration was high with over half of the patients experiencing these adverse effects. Several authors strongly propose screening programs for retinopathy in the early period after IFN administration. Pulmonary hypertension due to IFN therapy is a serious side effect due to its irreversible nature in most patients. Patients who develop signs of acute abdomen up to months after IFN administration should be rapidly assessed for potential adverse effects of IFN. The literature suggests a broad spectrum of vascular injuries to different organs in humans as adverse effects of IFN therapy in HCV-infected patients.

Keywords: HCV; Heart; Hepatitis C virus; Risk factor; Vascular disease.

Similar articles

See all similar articles

References

    1. Sagaster KP. [Interferon-alpha therapy in hypernephroma] Wien Med Wochenschr. 1993;143:443–7. PubMed PMID: 8273370. - PubMed
    1. Wu JM, Lin CS, Wang JN, Luo CY, Yu CY, Yang HB. Pulmonary cavernous hemangiomatosis treated with interferon alfa-2a. Pediatr Cardiol. 1996;17:332–4. PubMed PMID: 8660452. - PubMed
    1. Kölby L, Persson G, Franzén S, Ahrén B. Randomized clinical trial of the effect of interferon alpha on survival in patients with disseminated midgut carcinoid tumours. Br J Surg. 2003;90:687–93. PubMed PMID: 12808615. - PubMed
    1. Chopra A, Klein PL, Drinnan T, Lee SS. How to optimize HCV therapy in genotype 1 patients: management of side-effects. Liver Int. 2013;33 Suppl 1:30–4. doi: 10.1111/liv.12080. PubMed PMID: 23286843. - PubMed
    1. Giannini EG, Basso M, Savarino V, Picciotto A. Predictive factors for response to peginterferon-alpha and ribavirin treatment of chronic HCV infection in patients aged 65 years and more. Dig Dis Sci. 2010;55:3193–9. doi: 10.1007/s10620-010-1408-x. PubMed PMID: 20848200. - PubMed

LinkOut - more resources

Feedback